The celebrex long-term safety data published in the NEJM show it's a better drug than ibuprofen - clearly better on kidney and GI and very likely better on cardiac.
All the press you see will be very hedged because this was a non-inferiority trial and technically didn't allow proper superiority comparisons. But I would ignore the statisticians on this one - the HR's are clear.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.